Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y.

Nat Genet. 2009 Oct;41(10):1127-32. doi: 10.1038/ng.438. Epub 2009 Aug 30.

2.

ERBB4 mutation analysis: emerging molecular target for melanoma treatment.

Lau C, Killian KJ, Samuels Y, Rudloff U.

Methods Mol Biol. 2014;1102:461-80. doi: 10.1007/978-1-62703-727-3_24.

3.

A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.

Settleman J.

Cancer Cell. 2009 Oct 6;16(4):278-9. doi: 10.1016/j.ccr.2009.09.013.

4.

ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).

Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, Walz TM.

Melanoma Res. 2009 Jun;19(3):156-66. doi: 10.1097/CMR.0b013e32832c6339.

PMID:
19434003
5.

Mutations in ERBB4 may have a minor role in melanoma pathogenesis.

Manca A, Lissia A, Cossu A, Rubino C, Ascierto PA, Stanganelli I, Palmieri G.

J Invest Dermatol. 2013 Jun;133(6):1685-7. doi: 10.1038/jid.2013.27. Epub 2013 Jan 22. No abstract available.

6.

A growing family: adding mutated Erbb4 as a novel cancer target.

Rudloff U, Samuels Y.

Cell Cycle. 2010 Apr 15;9(8):1487-503. Epub 2010 Apr 15.

7.

Somatic mutations of the ERBB4 kinase domain in human cancers.

Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, Moon SW, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH.

Int J Cancer. 2006 Mar 15;118(6):1426-9.

8.

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, Stella A, Jensen-Jarolim E, Höller C, Wacheck V, Pehamberger H, Valent P.

PLoS One. 2014 Jan 29;9(1):e84417. doi: 10.1371/journal.pone.0084417. eCollection 2014.

9.

Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.

Bessette DC, Tilch E, Seidens T, Quinn MC, Wiegmans AP, Shi W, Cocciardi S, McCart-Reed A, Saunus JM, Simpson PT, Grimmond SM, Lakhani SR, Khanna KK, Waddell N, Al-Ejeh F, Chenevix-Trench G.

PLoS One. 2015 May 13;10(5):e0125232. doi: 10.1371/journal.pone.0125232. eCollection 2015.

10.

The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.

Zhou QM, Li W, Guan YX, Zhang X, Chen XC, Ding Y, Wen XZ, Peng RQ, Yan SM, Zhang XS.

Chin J Cancer. 2013 Jul;32(7):410-4. doi: 10.5732/cjc.012.10121. Epub 2012 Dec 14.

11.

Mutated ERBB4: a novel drug target in metastatic melanoma?

Kurppa K, Elenius K.

Pigment Cell Melanoma Res. 2009 Dec;22(6):708-10. doi: 10.1111/j.1755-148X.2009.00635.x. Epub 2009 Sep 7. No abstract available.

PMID:
19735458
12.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

13.

Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.

Yue L, Huang ZM, Fong S, Leong S, Jakowatz JG, Charruyer-Reinwald A, Wei M, Ghadially R.

Melanoma Res. 2015 Apr;25(2):138-48. doi: 10.1097/CMR.0000000000000144.

PMID:
25643237
14.

Cell differentiation and cell-cycle alterations by tyrosine kinase inhibitors in human melanoma cells.

Hartmann RR, Rimoldi D, Lejeune FJ, Carrel S.

Melanoma Res. 1997 Aug;7 Suppl 2:S27-33.

PMID:
9578414
15.

Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.

Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J.

Cancer Res. 2006 Apr 1;66(7):3828-35.

16.

Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.

Schönherr M, Bhattacharya A, Kottek T, Szymczak S, Köberle M, Wickenhauser C, Siebolts U, Saalbach A, Koczan D, Magin TM, Simon JC, Kunz M.

Pigment Cell Melanoma Res. 2014 May;27(3):418-30. doi: 10.1111/pcmr.12216. Epub 2014 Jan 31.

PMID:
24406113
17.

Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.

Niu HT, Zhou QM, Wang F, Shao Q, Guan YX, Wen XZ, Chen LZ, Feng QS, Li W, Zeng YX, Zhang XS.

Pigment Cell Melanoma Res. 2013 Sep;26(5):646-53. doi: 10.1111/pcmr.12129. Epub 2013 Jul 11.

PMID:
23751074
18.

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M.

Cell Cycle. 2015;14(4):648-55. doi: 10.4161/15384101.2014.994966. Erratum in: Cell Cycle. 2015;14(8):1339-41.

19.

The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.

Toyooka S, Date H, Uchida A, Kiura K, Takata M.

Clin Cancer Res. 2007 Jun 1;13(11):3431; author reply 3431-2. No abstract available.

20.

Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.

Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N, Ellis JJ, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer JM, Pollak T, Youngkin D, Brooks BR, Lanagan C, Schmidt CW, Kobe B, MacKeigan JP, Yin H, Brown KM, Gibbs R, Trent J, Hayward NK.

Nat Genet. 2011 Dec 25;44(2):165-9. doi: 10.1038/ng.1041.

Supplemental Content

Support Center